{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T03:07:27Z","timestamp":1790737647166,"version":"4.1.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,11,26]],"date-time":"2019-11-26T00:00:00Z","timestamp":1574726400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,11,26]],"date-time":"2019-11-26T00:00:00Z","timestamp":1574726400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hautarzt"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1007\/s00105-019-04514-0","type":"journal-article","created":{"date-parts":[[2019,11,26]],"date-time":"2019-11-26T12:03:09Z","timestamp":1574769789000},"page":"63-77","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Malignes Melanom","Malignant melanoma"],"prefix":"10.1007","volume":"71","author":[{"given":"Georg","family":"Lodde","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Zimmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth","family":"Livingstone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk","family":"Schadendorf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Selma","family":"Ugurel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,11,26]]},"reference":[{"issue":"10151","key":"4514_CR1","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/S0140-6736(18)31559-9","volume":"392","author":"D Schadendorf","year":"2018","unstructured":"Schadendorf\u00a0D, van Akkooi\u00a0ACJ, Berking\u00a0C, Griewank\u00a0KG, Gutzmer\u00a0R, Hauschild\u00a0A et\u00a0al (2018) Melanoma. Lancet 392(10151):971\u2013984. https:\/\/doi.org\/10.1016\/S0140-6736(18)31559-9","journal-title":"Lancet"},{"key":"4514_CR2","volume-title":"International Agency for Research on Cancer, WHO. CANCER TODAY","author":"World Health Organization","year":"2019","unstructured":"World Health Organization International Agency for Research on Cancer, WHO (2019) CANCER TODAY. http:\/\/gco.iarc.fr\/today\/online-analysis-multi-bars?v=2018&mode=cancer&mode_population=countries&population=900&populations=900&key=total&sex=0&cancer=39&type=0&statistic=5&prevalence=0&population_group=0&ages_group%5B%5D=0&ages_group%5B%5D=17&nb_items=20&group_cancer=1&include_nmsc=1&include_nmsc_other=1&type_multiple=%257B%2522inc%2522%253Atrue%252C%2522mort%2522%253Afalse%252C%2522prev%2522%253Afalse%257D&orientation=horizontal&type_sort=0&type_nb_items=%257B%2522top%2522%253Atrue%252C%2522bottom%2522%253Afalse%257D&population_group_globocan_id=. Zugegriffen: 30. Mai 2019"},{"key":"4514_CR3","volume-title":"Estimated age-standardized incidence rates (World) in 2018, melanoma of skin, both sexes, all ages","author":"World Health Organization International Agency for Research on Cancer","year":"2019","unstructured":"World Health Organization, International Agency for Research on Cancer (2019) Estimated age-standardized incidence rates (World) in 2018, melanoma of skin, both sexes, all ages. http:\/\/gco.iarc.fr\/today\/online-analysis-map?v=2018&mode=population&mode_population=continents&population=900&populations=900&key=asr&sex=0&cancer=16&type=0&statistic=5&prevalence=0&population_group=0&ages_group%5B%5D=0&ages_group%5B%5D=17&nb_items=5&group_cancer=0&include_nmsc=1&include_nmsc_other=1&projection=natural-earth&color_palette=default&map_scale=quantile&map_nb_colors=5&continent=0&rotate=%255B10%252C0%255D. Zugegriffen: 30. Mai 2019"},{"key":"4514_CR4","unstructured":"Robert-Koch-Institut (2016) Bericht zum Krebsgeschehen in Deutschland Available from: https:\/\/www.krebsdaten.de\/Krebs\/DE\/Content\/Publikationen\/Krebsgeschehen\/Krebsgeschehen_download.pdf?__blob=publicationFile. Zugegriffen: 30.05.2019"},{"issue":"20","key":"4514_CR5","doi-asserted-by":"publisher","first-page":"2135","DOI":"10.1056\/NEJMoa050092","volume":"353","author":"JA Curtin","year":"2005","unstructured":"Curtin\u00a0JA, Fridlyand\u00a0J, Kageshita\u00a0T, Patel\u00a0HN, Busam\u00a0KJ, Kutzner\u00a0H et\u00a0al (2005) Distinct sets of genetic alterations in melanoma. N\u00a0Engl J Med 353(20):2135\u20132147. https:\/\/doi.org\/10.1056\/NEJMoa050092","journal-title":"N Engl J Med"},{"issue":"3","key":"4514_CR6","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.canep.2017.04.004","volume":"48","author":"BK Armstrong","year":"2017","unstructured":"Armstrong\u00a0BK, Cust\u00a0AE (2017) Sun exposure and skin cancer, and the puzzle of cutaneous melanoma: A perspective on Fears et\u00a0al. Mathematical models of age and ultraviolet effects on the incidence of skin cancer among whites in the United States. Cancer Epidemiol 48:147\u2013156. https:\/\/doi.org\/10.1016\/j.canep.2017.04.004. Epub 2017 May 3","journal-title":"Cancer Epidemiol"},{"issue":"20","key":"4514_CR7","doi-asserted-by":"publisher","first-page":"1926","DOI":"10.1056\/NEJMoa1502583","volume":"373","author":"AH Shain","year":"2015","unstructured":"Shain\u00a0AH, Yeh\u00a0I, Kovalyshyn\u00a0I, Sriharan\u00a0A, Talevich\u00a0E, Gagnon\u00a0A et\u00a0al (2015) The genetic evolution of melanoma from precursor lesions. N\u00a0Engl J Med 373(20):1926\u20131936. https:\/\/doi.org\/10.1056\/NEJMoa1502583","journal-title":"N Engl J Med"},{"key":"4514_CR8","volume-title":"Braun-Falco\u2019s Dermatologie, Venerologie und Allergologie","author":"G Plewig","year":"2015","unstructured":"Plewig\u00a0G, Landthaler\u00a0M, Burgdorf\u00a0W, Hertl\u00a0M, Ruzicka\u00a0T (2015) Braun-Falco\u2019s Dermatologie, Venerologie und Allergologie, 6.\u00a0Aufl.","edition":"6"},{"issue":"5","key":"4514_CR9","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1067\/mjd.2003.216","volume":"48","author":"AJ Chamberlain","year":"2003","unstructured":"Chamberlain\u00a0AJ, Fritschi\u00a0L, Kelly\u00a0JW (2003) Nodular melanoma: patients\u2019 perceptions of presenting features and implications for earlier detection. J\u00a0Am Acad Dermatol 48(5):694\u2013701. https:\/\/doi.org\/10.1067\/mjd.2003.216","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"4514_CR10","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1001\/archderm.142.4.447","volume":"142","author":"JK Robinson","year":"2006","unstructured":"Robinson\u00a0JK, Turrisi\u00a0R (2006) Skills training to learn discrimination of ABCDE criteria by those at risk of developing melanoma. Arch Dermatol 142(4):447\u2013452. https:\/\/doi.org\/10.1001\/archderm.142.4.447","journal-title":"Arch Dermatol"},{"issue":"22","key":"4514_CR11","doi-asserted-by":"publisher","first-page":"2771","DOI":"10.1001\/jama.292.22.2771","volume":"292","author":"NR Abbasi","year":"2004","unstructured":"Abbasi\u00a0NR, Shaw\u00a0HM, Rigel\u00a0DS, Friedman\u00a0RJ, McCarthy\u00a0WH, Osman\u00a0I et\u00a0al (2004) Early diagnosis of cutaneous melanoma: revisiting the ABCD criteria. JAMA 292(22):2771\u20132776. https:\/\/doi.org\/10.1001\/jama.292.22.2771","journal-title":"JAMA"},{"key":"4514_CR12","unstructured":"Leitlinienprogramm Onkologie der Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften e.\u202fV. (AWMF), Deutschen Krebsgesellschaft e.\u202fV. (DKG), Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF) Diagnostik, Therapie und Nachsorge des Melanoms, Langversion 3.1, 2018, AWMF Registernummer: 032\/024OL. http:\/\/www.leitlinienprogramm-onkologie.de\/leitlinien\/melanom\/. Zugegriffen: 2. Juni 2019"},{"key":"4514_CR13","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.ejca.2017.11.023","volume":"91","author":"JJ Grob","year":"2018","unstructured":"Grob\u00a0JJ, Schadendorf\u00a0D, Lorigan\u00a0P, Ascierto\u00a0P, Larkin\u00a0J, Nathan\u00a0P et\u00a0al (2018) Eighth American Joint Committee on Cancer (AJCC) melanoma classification: let us reconsider stage III. Eur J Cancer 91:168\u2013170. https:\/\/doi.org\/10.1016\/j.ejca.2017.11.023","journal-title":"Eur J Cancer"},{"issue":"6","key":"4514_CR14","doi-asserted-by":"publisher","first-page":"472","DOI":"10.3322\/caac.21409","volume":"67","author":"JE Gershenwald","year":"2017","unstructured":"Gershenwald\u00a0JE, Scolyer\u00a0RA, Hess\u00a0KR, Sondak\u00a0VK, Long\u00a0GV, Ross\u00a0MI et al (2017) Melanoma staging: evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin 67(6):472\u2013492. https:\/\/doi.org\/10.3322\/caac.21409","journal-title":"CA Cancer J Clin"},{"issue":"7","key":"4514_CR15","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.1016\/j.cell.2015.05.044","volume":"161","author":"Cancer Genome Atlas Network","year":"2015","unstructured":"Cancer Genome Atlas Network (2015) Genomic classification of cutaneous melanoma. Cell 161(7):1681\u20131696. https:\/\/doi.org\/10.1016\/j.cell.2015.05.044","journal-title":"Cell"},{"issue":"11","key":"4514_CR16","doi-asserted-by":"publisher","first-page":"4179","DOI":"10.1172\/JCI91258","volume":"127","author":"Y Zhan","year":"2017","unstructured":"Zhan\u00a0Y, Guo\u00a0J, Yang\u00a0W, Goncalves\u00a0C, Rzymski\u00a0T, Dreas\u00a0A et al (2017) MNK1\/2 inhibition limits oncogenicity and metastasis of KIT-mutant melanoma. J\u00a0Clin Invest 127(11):4179\u20134192. https:\/\/doi.org\/10.1172\/JCI91258","journal-title":"J Clin Invest"},{"issue":"2","key":"4514_CR17","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/S1470-2045(15)00482-9","volume":"17","author":"AJ Hayes","year":"2016","unstructured":"Hayes\u00a0AJ, Maynard\u00a0L, Coombes\u00a0G, Newton-Bishop\u00a0J, Timmons\u00a0M, Cook\u00a0M et al (2016) Wide versus narrow excision margins for high-risk, primary cutaneous melanomas: Long-term follow-up of survival in a\u00a0randomised trial. Lancet Oncol 17(2):184\u2013192. https:\/\/doi.org\/10.1016\/S1470-2045(15)00482-9","journal-title":"Lancet Oncol"},{"issue":"23","key":"4514_CR18","doi-asserted-by":"publisher","first-page":"2211","DOI":"10.1056\/NEJMoa1613210","volume":"376","author":"MB Faries","year":"2017","unstructured":"Faries\u00a0MB, Thompson\u00a0JF, Cochran\u00a0AJ, Andtbacka\u00a0RH, Mozzillo\u00a0N, Zager\u00a0JS et al (2017) Completion dissection or observation for sentinel-node metastasis in melanoma. N\u00a0Engl J Med 376(23):2211\u20132222. https:\/\/doi.org\/10.1056\/NEJMoa1613210","journal-title":"N Engl J Med"},{"issue":"5","key":"4514_CR19","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1016\/S1470-2045(15)70122-1","volume":"16","author":"AMM Eggermont","year":"2015","unstructured":"Eggermont\u00a0AMM, Chiarion-Sileni\u00a0V, Grob\u00a0J\u2011J, Dummer\u00a0R, Wolchok\u00a0JD, Schmidt\u00a0H et al (2015) Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial. Lancet Oncol 16(5):522\u2013530. https:\/\/doi.org\/10.1016\/S1470-2045(15)70122-1","journal-title":"Lancet Oncol"},{"issue":"15_suppl","key":"4514_CR20","doi-asserted-by":"publisher","first-page":"9500","DOI":"10.1200\/JCO.2017.35.15_suppl.9500","volume":"35","author":"AA Tarhini","year":"2017","unstructured":"Tarhini\u00a0AA, Lee\u00a0SJ, Hodi\u00a0FS, Rao\u00a0UNM, Cohen\u00a0GI, Hamid\u00a0O et al (2017) A phase III randomized study of adjuvant ipilimumab (3 or 10\u202fmg\/kg) versus high-dose interferon alfa-2b for resected high-risk melanoma (U.S. Intergroup E1609): Preliminary safety and efficacy of the ipilimumab arms. J\u00a0Clin Oncol 35(15_suppl):9500. https:\/\/doi.org\/10.1200\/JCO.2017.35.15_suppl.9500","journal-title":"J Clin Oncol"},{"issue":"19","key":"4514_CR21","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1056\/NEJMoa1709030","volume":"377","author":"J Weber","year":"2017","unstructured":"Weber\u00a0J, Mandala\u00a0M, Del Vecchio\u00a0M, Gogas\u00a0HJ, Arance\u00a0AM, Cowey\u00a0CL et\u00a0al (2017) Adjuvant Nivolumab versus Ipilimumab in resected stage III or IV melanoma. N\u00a0Engl J Med 377(19):1824\u20131835. https:\/\/doi.org\/10.1056\/NEJMoa1709030","journal-title":"N Engl J Med"},{"issue":"19","key":"4514_CR22","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1056\/NEJMoa1802357","volume":"378","author":"AMM Eggermont","year":"2018","unstructured":"Eggermont\u00a0AMM, Blank\u00a0CU, Mandala\u00a0M, Long\u00a0GV, Atkinson\u00a0V, Dalle\u00a0S et\u00a0al (2018) Adjuvant pembrolizumab versus placebo in resected stage III melanoma. N\u00a0Engl J Med 378(19):1789\u20131801. https:\/\/doi.org\/10.1056\/NEJMoa1802357","journal-title":"N Engl J Med"},{"issue":"19","key":"4514_CR23","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1056\/NEJMoa1708539","volume":"377","author":"GV Long","year":"2017","unstructured":"Long\u00a0GV, Hauschild\u00a0A, Santinami\u00a0M, Atkinson\u00a0V, Mandal\u00e0\u00a0M, Chiarion-Sileni\u00a0V et al (2017) Adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma. N\u00a0Engl J Med 377(19):1813\u20131823. https:\/\/doi.org\/10.1056\/NEJMoa1708539","journal-title":"N Engl J Med"},{"key":"4514_CR24","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.ejca.2017.06.028","volume":"83","author":"S Ugurel","year":"2017","unstructured":"Ugurel\u00a0S, R\u00f6hmel\u00a0J, Ascierto\u00a0PA, Flaherty\u00a0KT, Grob\u00a0JJ, Hauschild\u00a0A et al (2017) Survival of patients with advanced metastatic melanoma: the impact of novel therapies-update 2017. Eur J Cancer 83:247\u2013257. https:\/\/doi.org\/10.1016\/j.ejca.2017.06.028","journal-title":"Eur J Cancer"},{"issue":"17","key":"4514_CR25","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.1200\/JCO.2014.56.2736","volume":"33","author":"D Schadendorf","year":"2015","unstructured":"Schadendorf\u00a0D, Hodi\u00a0FS, Robert\u00a0C, Weber\u00a0JS, Margolin\u00a0K, Hamid\u00a0O et al (2015) Pooled analysis of long-term survival data from phase II and phase III trials of Ipilimumab in unresectable or metastatic melanoma. J\u00a0Clin Oncol 33(17):1889\u20131894. https:\/\/doi.org\/10.1200\/JCO.2014.56.2736","journal-title":"J Clin Oncol"},{"issue":"11","key":"4514_CR26","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1016\/S1470-2045(18)30700-9","volume":"19","author":"FS Hodi","year":"2018","unstructured":"Hodi\u00a0FS, Chiarion-Sileni\u00a0V, Gonzalez\u00a0R, Grob\u00a0J\u2011J, Rutkowski\u00a0P, Cowey\u00a0CL et al (2018) Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4\u2011year outcomes of a\u00a0multicentre, randomised, phase 3 trial. Lancet Oncol 19(11):1480\u20131492. https:\/\/doi.org\/10.1016\/S1470-2045(18)30700-9","journal-title":"Lancet Oncol"},{"issue":"15_suppl","key":"4514_CR27","doi-asserted-by":"publisher","first-page":"9508","DOI":"10.1200\/JCO.2017.35.15_suppl.9508","volume":"35","author":"GV Long","year":"2017","unstructured":"Long\u00a0GV, Atkinson\u00a0V, Menzies\u00a0AM, Lo\u00a0S, Guminski\u00a0AD, Brown\u00a0MP et al (2017) A randomized phase II study of nivolumab or nivolumab combined with ipilimumab in patients (pts) with melanoma brain metastases (mets): The Anti-PD1 Brain Collaboration (ABC). J\u00a0Clin Oncol 35(15_suppl):9508. https:\/\/doi.org\/10.1200\/JCO.2017.35.15_suppl.9508","journal-title":"J Clin Oncol"},{"issue":"5","key":"4514_CR28","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1016\/S1470-2045(17)30231-0","volume":"18","author":"PA Ascierto","year":"2017","unstructured":"Ascierto\u00a0PA, Del Vecchio\u00a0M, Robert\u00a0C, Mackiewicz\u00a0A, Chiarion-Sileni\u00a0V, Arance\u00a0A et al (2017) Ipilimumab 10\u202fmg\/kg versus ipilimumab 3\u202fmg\/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial. Lancet Oncol 18(5):611\u2013622. https:\/\/doi.org\/10.1016\/S1470-2045(17)30231-0","journal-title":"Lancet Oncol"},{"key":"4514_CR29","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.ejca.2016.02.025","volume":"60","author":"L Hofmann","year":"2016","unstructured":"Hofmann\u00a0L, Forschner\u00a0A, Loquai\u00a0C, Goldinger\u00a0SM, Zimmer\u00a0L, Ugurel\u00a0S et al (2016) Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD\u20111 therapy. Eur J Cancer 60:190\u2013209. https:\/\/doi.org\/10.1016\/j.ejca.2016.02.025","journal-title":"Eur J Cancer"},{"key":"4514_CR30","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.ejca.2016.02.024","volume":"60","author":"L Zimmer","year":"2016","unstructured":"Zimmer\u00a0L, Goldinger\u00a0SM, Hofmann\u00a0L, Loquai\u00a0C, Ugurel\u00a0S, Thomas\u00a0I et al (2016) Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD\u20111 therapy. Eur J Cancer 60:210\u2013225. https:\/\/doi.org\/10.1016\/j.ejca.2016.02.024","journal-title":"Eur J Cancer"},{"issue":"1","key":"4514_CR31","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1056\/NEJMoa1412690","volume":"372","author":"C Robert","year":"2015","unstructured":"Robert\u00a0C, Karaszewska\u00a0B, Schachter\u00a0J, Rutkowski\u00a0P, Mackiewicz\u00a0A, Stroiakovski\u00a0D et\u00a0al (2015) Improved overall survival in melanoma with combined dabrafenib and trametinib. N\u00a0Engl J Med 372(1):30\u201339. https:\/\/doi.org\/10.1056\/NEJMoa1412690","journal-title":"N Engl J Med"},{"issue":"5","key":"4514_CR32","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1016\/S1470-2045(18)30142-6","volume":"19","author":"R Dummer","year":"2018","unstructured":"Dummer\u00a0R, Ascierto\u00a0PA, Gogas\u00a0HJ, Arance\u00a0A, Mandala\u00a0M, Liszkay\u00a0G et al (2018) Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): A multicentre, open-label, randomised phase 3 trial. Lancet Oncol 19(5):603\u2013615. https:\/\/doi.org\/10.1016\/S1470-2045(18)30142-6","journal-title":"Lancet Oncol"},{"issue":"7","key":"4514_CR33","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1056\/NEJMoa1904059","volume":"381","author":"C Robert","year":"2019","unstructured":"Robert\u00a0C, Grob\u00a0JJ, Stroyakovskiy\u00a0D, Karaszewska\u00a0B, Hauschild\u00a0A, Levchenko\u00a0E et al (2019) Five-year outcomes with dabrafenib plus trametinib in metastatic melanoma. N\u00a0Engl J Med 381(7):626\u2013636. https:\/\/doi.org\/10.1056\/NEJMoa1904059","journal-title":"N Engl J Med"},{"issue":"7","key":"4514_CR34","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1016\/S1470-2045(17)30429-1","volume":"18","author":"MA Davies","year":"2017","unstructured":"Davies\u00a0MA, Saiag\u00a0P, Robert\u00a0C, Grob\u00a0J\u2011J, Flaherty\u00a0KT, Arance\u00a0A et al (2017) Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial. Lancet Oncol 18(7):863\u2013873. https:\/\/doi.org\/10.1016\/S1470-2045(17)30429-1","journal-title":"Lancet Oncol"},{"issue":"1","key":"4514_CR35","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1158\/2159-8290.CD-13-0617","volume":"4","author":"EM van Allen","year":"2014","unstructured":"van Allen\u00a0EM, Wagle\u00a0N, Sucker\u00a0A, Treacy\u00a0DJ, Johannessen\u00a0CM, Goetz\u00a0EM et\u00a0al (2014) The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma. Cancer Discov 4(1):94\u2013109. https:\/\/doi.org\/10.1158\/2159-8290.CD-13-0617","journal-title":"Cancer Discov"}],"container-title":["Der Hautarzt"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00105-019-04514-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00105-019-04514-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00105-019-04514-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,25]],"date-time":"2020-11-25T01:23:44Z","timestamp":1606267424000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00105-019-04514-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,26]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,1]]}},"alternative-id":["4514"],"URL":"https:\/\/doi.org\/10.1007\/s00105-019-04514-0","relation":{},"ISSN":["0017-8470","1432-1173"],"issn-type":[{"value":"0017-8470","type":"print"},{"value":"1432-1173","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,26]]},"assertion":[{"value":"26 November 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"Gem\u00e4\u00df den Richtlinien des Springer Medizin Verlags werden Autoren und Wissenschaftliche Leitung im Rahmen der Manuskripterstellung und Manuskriptfreigabe aufgefordert, eine vollst\u00e4ndige Erkl\u00e4rung zu ihren finanziellen und nichtfinanziellen Interessen abzugeben.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"<b>G.\u00a0Lodde<\/b>: A. Finanzielle Interessen: Reisekostenunterst\u00fctzung von Novartis. \u2013 B. Nichtfinanzielle Interessen: Wissenschaftlicher Angestellter, Klinik f\u00fcr Dermatologie, Venerologie und Allergologie, Universit\u00e4tsklinikum Essen. <b>L.\u00a0Zimmer<\/b>: A. Finanzielle Interessen: Honorar: Bristol-Myers Squibb (BMS), Pierre Fabre, Merck Sharp & Dohme (MSD), Novartis | Reise\u2011\/\u00dcbernachtungskosten: Amgen, Sanofi, Pierre Fabre, BMS. \u2013 Advisory Boards: BMS, MSD, Roche, Pierre Fabre, Sanofi, Novartis. \u2013 Patente, Gesch\u00e4ftsanteile, Aktien oder \u00c4hnliches an einer im Medizinbereich aktiven Firma: Bayer-Aktien. \u2013 B. Nichtfinanzielle Interessen: Ober\u00e4rztin Hauttumorzentrum Universit\u00e4tsklinikum Essen | Mitgliedschaften: ADO, DKG (Deutsche Krebsgesellschaft), DDG. <b>E. Livingstone<\/b>: A. Finanzielle Interessen: Referentenhonorar oder Kostenerstattung als passive Teilnehmerin: Beraterhonorare und\/oder Referentenhonorare von: Amgen, Actelion, Roche, BMS, MSD, Novartis, Janssen, Medac | Reisekostenzuschuss oder -erstattung von: Amgen, MSD, BMS, Pierre Fabre, Sun Pharma und Novartis. \u2013 B. Nichtfinanzielle Interessen: Wissenschaftliche Mitarbeiterin, Dermatologin (Ober\u00e4rztin), Klinik f\u00fcr Dermatologie, Universit\u00e4tsmedizin Essen, Essen | Mitgliedschaften: ADO, DDG, \u00c4rztinnenbund. <b>D. Schadendorf<\/b>: A. Finanzielle Interessen: Berater\u2011\/Referentenhonorar, Reise\u2011\/\u00dcbernachtungskosten: Roche, Novartis, BMS, MSD\/Merck, Merck-EMD, Amgen, Pierre Fabre, Pfizer, 4Sc, Philogen, LEO Pharma, Regeneron\/Sanofi, AstraZeneca, B\u00f6hringer-Ingelheim, MOLOGEN, InflaRX, NeraCare | Berater\u2011\/Referentenhonorar: Incyte, Array Biopharma | Beraterhonorar: Immunocore, Sysmex. \u2013 B. Nichtfinanzielle Interessen: Universit\u00e4tsklinikum Essen, Direktor der Klinik f\u00fcr Dermatologie und Direktor des Westdeutschen Tumorzentrums, Essen | Mitgliedschaften: DDG, \u201eAmerican Society of Cancer Research\u201c (ASCR), \u201eSociety of Investigative Dermatology\u201c (SID), \u201eEuropean Organization for Research and Treatment of Cancer\u201c (EORTC) \u2013 \u201eMelanoma Cooperative Group\u201c, DKG, Arbeitsgemeinschaft Dermatologische Onkologie \u2013 Mitglied seit 1996, Pr\u00e4sident 2002\u20132018, \u201eAmerican Society of Clinical Oncology\u201c (ASCO), Mitglied im \u201eEditorial Board of the EJC\u201c (EJC: \u201eEuropean Journal of Cancer\u201c), Gr\u00fcndungsmitglied der \u201eEuropean Society for Cancer Immunology and Immunotherapy\u201c (ESCII), \u201eAssociation for Cancer Immunotherapy\u201c (CIMT). <b>S. Ugurel<\/b>: A. Finanzielle Interessen: Forschungsunterst\u00fctzung: Bristol-Myers Squibb und Merck Serono. \u2013 Reisekostenunterst\u00fctzung: Bristol-Myers Squibb, Merck Sharp & Dohme. \u2013 Bezahlte Beraterin\/interne Schulungsreferentin\/Gehaltsempf\u00e4ngerin oder \u00c4hnliches: Bristol-Myers Squibb, Merck Sharp & Dohme, Merck Serono, Novartis, Roche. \u2013 B. Nichtfinanzielle Interessen: Ober\u00e4rztin an Universit\u00e4tsklinik | Vorstandsmitglied AG (Arbeitsgemeinschaft) Dermatologische Onkologie der DKG.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Autoren"}},{"value":"Die vollst\u00e4ndige Erkl\u00e4rung zum Interessenkonflikt der Wissenschaftlichen Leitung finden Sie am Kurs der zertifizierten Fortbildung auf .","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Wissenschaftliche Leitung"}},{"value":"erkl\u00e4rt, dass f\u00fcr die Publikation dieser CME-Fortbildung keine Sponsorengelder an den Verlag flie\u00dfen.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Der Verlag"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autoren keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Der Verlag"}}]}}